Trial
NCT00510289
Sorafenib in Myelodysplastic Syndrome
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Duke University
Collaborators
Bayer
Condition
Myelodysplastic Syndromes
Intervention
Sorafenib
Why stopped
Early closure of study due to poor response
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-04-19